Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.

Menarini Group News

2011 - 11 - 15

Singapore – Florence 15th November 2011: Menarini succeeds in bid for Invida Group

Florence, 15th November 2011


Singapore – Florence 15th November 2011: Menarini succeeds in bid for Invida Group

Singapore, Australia, China, Hong Kong, India, Indonesia, Malaysia, New Zealand, South Korea, Taiwan, Thailand, The Philippines, and Vietnam: these are the nations into which the Florence-based Italian multinational Menarini shall now be expanding following its acquisition of Invida Group Private Limited of Singapore from Temasek Holdings (an Asian Investment company headquartered in Singapore), Quintiles (a U.S. bio and pharmaceutical services provider) and Zuellig (an Asian leading healthcare distributor).

Invida Group is one of the leading pharmaceutical companies currently operating in the Asia - Pacific region, an area which represents 10% of the world’s pharmaceutical market with a 20% annual growth rate. With an annual turnover exceeding USD 220 million (EUR 160m), 3,500 employees and a consolidated presence in extremely important therapeutic areas, Invida is considered by Menarini to be the ideal company to act as gateway to many of the most significant emerging countries with the world’s highest growth rates. Financial terms of the deal have not been disclosed.

The development plan foreseen by Menarini for the Invida Group underscores how Menarini in all its acquisitions has always opted to maximise local identity, culture and skills hence guaranteeing Invida, and its professionals, a future built around a dynamic and entrepreneurial vision.

“We have been committed to the prospect of acquiring Invida over the past few months”, commented Alberto Giovanni Aleotti, who, alongside the company’s General Manager, Piero Corsa, headed the Menarini task force engaged in the negotiations. “Once again, our team has worked with extraordinary dedication and I would like to take this opportunity to thank each and every team member.”

Dr. Aleotti added, “We look forward to gaining first-hand experience of the great vitality this region brings. It is a place where one can find a true concentration of highly skilled professionals and companies, thanks to the Singaporean Government’s policies that support business growth and innovation”.

“In Invida, we have found the “Menarini of Asia”, and a team of executives who possess exceptional competencies,” commented the two General Managers at Menarini, Piero Corsa and Domenico Simone, highlighting the great potential and opportunities behind this acquisition. “Invida will become Menarini’s Asia-Pacific headquarters, located in Singapore. It is ideal since it provides a bridge between Europe and Asia. Our goal is to provide patients in the Asia Pacific region access to our medicines.”

“This acquisition enables Invida to continue to grow our company as the commercialisation specialist in the Asia-Pacific pharmaceutical markets,” said Invida Chief Executive Officer John Graham. “The opportunities presented by this deal will allow both companies to achieve greater success by combining resources.”

Mr. John Graham, Chief Executive Officer of Invida will continue to lead the Asia Pacific operations.

Lucia Aleotti, Vice President of the Board of the Menarini Group concluded: “We are enthusiastic about this new, exciting opportunity. It opens up fresh prospects for expansion into a fast growing area, and it will bring new highly skilled competencies to Menarini and in turn, Invida gets access to the vast resources of Menarini”.

For further information please contact Press Office